• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Hoffman Robert E.

    4/2/25 4:15:48 PM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ESPR alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    Hoffman Robert E.

    (Last) (First) (Middle)
    C/O ESPERION THERAPEUTICS, INC.
    3891 RANCHERO DRIVE, SUITE 150

    (Street)
    ANN ARBOR MI 48108

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    04/01/2025
    3. Issuer Name and Ticker or Trading Symbol
    Esperion Therapeutics, Inc. [ ESPR ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    Remarks:
    No securities are beneficially owned.
    /s/ Sheldon L. Koenig, by power of attorney 04/02/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ESPR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ESPR

    DatePrice TargetRatingAnalyst
    12/18/2024$4.00Neutral
    Goldman
    12/17/2024$8.00Overweight
    Cantor Fitzgerald
    6/20/2024$2.50Neutral → Underperform
    BofA Securities
    1/3/2024Buy → Neutral
    BofA Securities
    11/20/2023Neutral
    JP Morgan
    8/1/2023Under Perform → Market Perform
    Northland Capital
    6/15/2023$1.25 → $4.00Underperform → Buy
    BofA Securities
    3/16/2023$1.00Market Perform → Under Perform
    Northland Capital
    More analyst ratings

    $ESPR
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:30 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

      3/25/24 4:41:37 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

      Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

      3/25/24 4:41:29 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commercial Officer Warren Eric sold $106 worth of shares (108 units at $0.98), decreasing direct ownership by 0.03% to 370,218 units (SEC Form 4)

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      4/21/25 4:04:07 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial Officer Halladay Benjamin sold $8 worth of shares (8 units at $0.96), decreasing direct ownership by 0.00% to 481,702 units (SEC Form 4)

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      4/21/25 4:03:41 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Hoffman Robert E.

      4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)

      4/2/25 4:19:14 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Esperion Therapeutics Inc.

      10-Q - Esperion Therapeutics, Inc. (0001434868) (Filer)

      5/8/25 9:01:06 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Esperion Therapeutics, Inc. (0001434868) (Filer)

      5/6/25 7:25:47 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Esperion Therapeutics Inc.

      424B5 - Esperion Therapeutics, Inc. (0001434868) (Filer)

      4/30/25 4:01:29 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ESPR
    Leadership Updates

    Live Leadership Updates

    See more

    $ESPR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference

      ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcar

      5/9/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on t

      5/8/25 4:30:00 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HLS Therapeutics Announces Q1 2025 Financial Results

      Total Product revenue grew 5% compared to Q1 2024, with growth across both the US and CanadaCanadian Product revenue grew 13% (in local currency) compared to Q1 2024, driven by 34% year-over-year growth in Vascepa net sales Adjusted EBITDA grew 41% (or 78% excluding royalty revenue) compared to Q1 2024HLS expands Cardiovascular portfolio by securing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended Marc

      5/8/25 6:32:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

      – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive

      4/24/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025

      ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive into Esperion's research and development strategy. Discussions will highlight Esperion's advancements and novel insights into ATP citrate lyase (ACLY) biology and the therapeutic role these next-generation inhibitors can play in multiple life-threatening diseases such as rare and chronic liver and kidney diseases. Additionally, Esperion will unveil a new indicati

      4/10/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Appoints Robert E. Hoffman to Board of Directors

      - Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025. "We are pleased to welcome Robert to the Esperion Board, confident that his decades of leadership within the biopharmaceutical sector will be of great benefit as we engage in our co

      4/1/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Esperion Therapeutics with a new price target

      Goldman initiated coverage of Esperion Therapeutics with a rating of Neutral and set a new price target of $4.00

      12/18/24 7:29:57 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Esperion Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Esperion Therapeutics with a rating of Overweight and set a new price target of $8.00

      12/17/24 7:45:32 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Therapeutics downgraded by BofA Securities with a new price target

      BofA Securities downgraded Esperion Therapeutics from Neutral to Underperform and set a new price target of $2.50

      6/20/24 7:33:38 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/14/24 8:42:21 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/12/24 2:23:13 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Esperion Therapeutics Inc.

      SC 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)

      11/4/24 1:33:59 PM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ESPR
    Financials

    Live finance-specific insights

    See more
    • HLS Therapeutics Announces Q1 2025 Financial Results

      Total Product revenue grew 5% compared to Q1 2024, with growth across both the US and CanadaCanadian Product revenue grew 13% (in local currency) compared to Q1 2024, driven by 34% year-over-year growth in Vascepa net sales Adjusted EBITDA grew 41% (or 78% excluding royalty revenue) compared to Q1 2024HLS expands Cardiovascular portfolio by securing Canadian rights to NEXLETOL® and NEXLIZET® from Esperion TherapeuticsTORONTO, May 8, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces its financial results for the three months ended Marc

      5/8/25 6:32:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion Reports First Quarter 2025 Financial Results

      – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the first quarter ended March 31, 202

      5/6/25 6:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Esperion to Report First Quarter 2025 Financial Results on May 6

      ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial stage biopharmaceutical company f

      4/23/25 8:00:00 AM ET
      $ESPR
      Biotechnology: Pharmaceutical Preparations
      Health Care